The Kinghorn Centre for Clinical Genomics (KCCG) is led by Associate Professor Marcel Dinger and comprises five programs that work closely together.
Since 2012, KCCG grew to more than 60 team members with skills across sequencing, informatics, clinical interpretation, business development, and education. In 2016, Garvan launched its wholly-owned subsidiary, Genome.One to provide genetic answers to health questions through clinical whole genome sequencing and analysis. Since that time, KCCG has started to reorganise into five new research programs and a management team:
|Centre management||Clinical genome informatics||Genomic technologies|
|Cancer Genomics||Population-scale Health Analytics|
The Centre management team is responsible for the broad oversight of KCCG operations. This includes: the management of flagship-sequencing projects initiated through the Sydney Genomics Collaborative; the management and promotion of KCCG sequencing services to both the national and international research community; the development and maintenance of new and on going collaborations and partnerships; and the procurement of external funding for genomic research and infrastructure.
|Dr Andrew Stone||Dr Marie-Jo Brion||Melissa Vincent|
This team has been brought together to advance the state-of-the-art in whole genome interpretation for the clinic. It will develop new tools and algorithms for reliably identifying and classifying noncoding regions of the genome that could directly relate to disease pathogenicity, with the aim of expanding the scope of clinical reporting. This team would advance the field of whole genome interpretation and enable translation of this research to Genome.One, so that it has access to the most advanced approaches in clinical interpretation.
|Alexander Drew||Dr Andre Minoche||Nenad Bartonicek||Clare Puttick|
|Dr Kishore Kumar||Dr Lisa Ewans||Dr Amali Mallawaarachchi||Mahdi Zeraati|
|Madhura Bakshi||Beth Signal||James Torpy|
This team will be responsible for evaluating new genomics technologies for both for clinical and research applications and, where appropriate, establish a pathway for translation of new technologies and techniques into Genome.One.
|Martin Smith||James Ferguson|
This group will research and develop clinically robust methods and pipelines to enable a scalable and economic approach to sequencing and analyzing cancer genomes and returning clinically valuable reports. This group will work closely with the Genomic Technologies group to develop state of the art cancer tests.
|Dr Mark Cowley||Dr Mark McCabe||Marie Wong||Brian Gloss|
|John Grady||Dr Velimir Gayevskiy||Nissa Sheriff|
This team, led by Dr Tudor Groza and Dr Warren Kaplan will focus on devising computational approaches to infer actionable knowledge from large-scale genotype – phenotype associations. Particular topics will include population statistical genomics, text/data mining and Machine Learning from EHRs, building temporal disease models from the genome – phenome – exposome triumvirate. The aim is to provide an analytical framework to cover the diagnosis – prevention continuum for improved clinical and patient care.
|Dr Tudor Groza||Dr Warren Kaplan||Dmitry Degrave||Shane Husson|
|Dr Simon Kocbek||Derrick Lin||Dr Frank Lin||
Our education and engagement program, led by Bronwyn Terrill, focuses on engaging health care professionals and the diverse communities that make up our population with the complex and fast-moving field of genomics.
|Bronwyn Terrill||Krista Recsei||Andrew Gibb||Ben Hall|
The impact of clinical genomics is becoming widespread and its importance to diverse disciplines is becoming increasingly recognised. KCCG engages closely with scientists, clinicians and ethicists through visiting appointments. These individuals bring additional expertise to KCCG and provide a mechanism for reciprocal engagement into the broader genomics community.
|Prof Andreas Zankl||Dr Jacqueline Savard||Dr Paul Lacaze||
|Dr Elizabeth Palmer|